Personal information

Emails & domains

Verified email domains

Other IDs

SciProfiles: 2244673

Activities

Collapse all

Works (5)

Unveiling the Inflammatory Landscape of Recurrent Glioblastoma through Histological-Based Assessments

Cancers
2024-09 | Journal article | Author
DOI: 10.3390/cancers16193283
Contributors: Nicholas B. Dadario; Deborah M. Boyett; Damian E. Teasley; Peter J. Chabot; Nathan J. Winans; Michael Argenziano; Colin P. Sperring; Peter Canoll; Jeffrey Bruce
Source: check_circle
Multidisciplinary Digital Publishing Institute

A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma

Pharmaceuticals
2024-07 | Journal article | Author
DOI: 10.3390/ph17080973
Contributors: Nathaniel W. Rolfe; Nicholas B. Dadario; Peter Canoll; Jeffrey Bruce
Source: check_circle
Multidisciplinary Digital Publishing Institute

C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo

Biomedicines
2023-01 | Journal article | Author
DOI: 10.3390/biomedicines11010137
Contributors: Robert L. Fine; Yuehua Mao; Richard Dinnen; Ramon V. Rosal; Anthony Raffo; Uri Hochfeld; Patrick Senatus; Jeffrey Bruce; Gwen Nichols; Hsin Wang et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System

Cancers
2023-01 | Journal article | Author
DOI: 10.3390/cancers15030876
Contributors: Connor Kinslow; Ali Rae; Prashanth Kumar; Guy M. McKhann; Michael B. Sisti; Jeffrey Bruce; James B. Yu; Simon K. Cheng; Tony Wang
Source: check_circle
Multidisciplinary Digital Publishing Institute

Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience

Pharmaceutics
2020-12 | Journal article | Author
DOI: 10.3390/pharmaceutics13010039
Contributors: Pavan Upadhyayula; Eleonora F. Spinazzi; Michael Argenziano; Peter Canoll; Jeffrey Bruce
Source: check_circle
Multidisciplinary Digital Publishing Institute
How many people are using ORCID?